{"id":87,"date":"2021-07-29T07:27:27","date_gmt":"2021-07-29T07:27:27","guid":{"rendered":"https:\/\/bioacq.wpengine.com\/?page_id=87"},"modified":"2021-08-11T02:55:30","modified_gmt":"2021-08-11T02:55:30","slug":"team","status":"publish","type":"page","link":"https:\/\/bioacq.com\/?page_id=87","title":{"rendered":"Team"},"content":{"rendered":"\n
<\/div>
\n
\n

Meet Our Executive Team<\/strong><\/h1>\n<\/div>\n<\/div><\/section>\n\n\n\n
<\/div>
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n
Chief Executive Officer, Chairman<\/strong><\/div>\n\n\n\n

Dr. Michael Shleifer<\/h2>\n\n\n\n
  • Co-founder and Managing Partner of SPRIM, a consulting and CRO services firm employing 500 people across 17 countries<\/li>
  • Founder of SPRIM Ventures, an investment firm focused in biotech and digital health solutions, with portfolio company aggregate valuations of over $200mm<\/li>
  • Prior position: 
    • Marketing for L\u2019Oreal<\/li><\/ul><\/li>
    • Education: 
      • PhD, Pharmacology from Universit\u00e9 Paris Descartes, Paris V.<\/li>
      • Masters, Biochemistry from Universit\u00e9 Paris Descartes, Paris V,<\/li>
      • Masters, Political Science and Economics from Institut d\u2019Etudes politiques de Paris (Sciences Po Paris)<\/li><\/ul><\/li><\/ul>\n<\/div>\n<\/div><\/section>\n\n\n\n
        <\/div>
        \n
        \n
        \"\"<\/figure>\n<\/div>\n\n\n\n
        \n
        Chief Operating Officer<\/strong><\/div>\n\n\n\n

        Ivan Jarry<\/h2>\n\n\n\n
        • Co-founder and Managing Partner of SPRIM<\/li>
        • Chief Executive Officer of ObvioHealth<\/li>
        • Ivan has created and grown over 40 companies in the health innovation space, including consulting practices, to CROs, \u200band ventures focused in digital health and biotech<\/li>
        • His expertise lies in seeding and structuring businesses for rapid growth through platform and process scalability, data integration and effective leadership, which has translated to significant growth in both revenue (up to 7 times year-over-year) and valuation (more than $200 million over the past 2 years) for the ventures under his leadership<\/li>
        • He has lived and worked in 8 countries and is fluent in 4 languages<\/li>
        • Education: 
          • Masters, EDHEC Business School in France<\/li><\/ul><\/li><\/ul>\n<\/div>\n<\/div><\/section>\n\n\n\n
            <\/div>
            \n
            \n
            \"\"<\/figure>\n<\/div>\n\n\n\n
            \n
            Chief Investment Officer, Director<\/strong><\/div>\n\n\n\n

            Albert Hummel<\/h2>\n\n\n\n
            • Senior Partner of SPRIM<\/li>
            • Over 40 years of diverse business and capital markets experience with a history of recognizing valuable business opportunities early on and capitalizing on their intrinsic value, especially in the healthcare market<\/li>
            • Prior positions:  
              • Chief Executive Officer of Obagi Medical Products<\/li>
              • Chief Executive Officer and Director of Cobrek Pharmaceuticals, where he led the company out of near bankruptcy by instituting a system to locate and exploit special market situations within specific drug sectors, leading to shorter drug discovery process and a reduction in drug development time. Cobrek was sold to Perrigo in 2012<\/li>
              • Chief Financial Officer of Watson Pharmaceuticals, overseeing the firm IPO and developing its funding strategy. Al sat on the Board for 28 years as well. Watson became Allergan PLC through multiple acquisitions<\/li>
              • CEO, President, Co-Founder, and Board Member of Bradley-Hummel & Company, a firm providing investment banking services in the healthcare, energy and financial service industries<\/li>
              • Vice President of Merrill Lynch, where he served provided investment banking services to private, corporate, and government (US and foreign) clients<\/li>
              • Education  
                • MBA, Indiana University<\/li><\/ul><\/li><\/ul><\/li><\/ul>\n<\/div>\n<\/div><\/section>\n\n\n\n
                  <\/div>
                  \n
                  \n
                  \"\"<\/figure>\n<\/div>\n\n\n\n
                  \n
                  Chief Financial Officer, Treasurer<\/strong><\/div>\n\n\n\n

                  Thomas Fratacci<\/h2>\n\n\n\n
                  • Group CFO of SPRIM and SPRIM Ventures, responsible for all finance functions within the Group and for developing robust business models to support financing rounds and exits<\/li>
                  • Thomas participated in the early years of SPRIM\u2019s development, both in Asia and the US<\/li>
                  • He has 20 years of experience in corporate finance and business management in B2B environments<\/li>
                  • Prior positions: Thomas started his career in financial audit and advisory services, first with Arthur Andersen and then with KPMG<\/li>
                  • He spent 8 years with the WPP Group as the CEO\/CFO for Kantar AV France, overseeing consulting activities in France and Russia, and managing a team of over 40<\/li>
                  • Education: Masters, EDHEC Business School in France<\/li><\/ul>\n<\/div>\n<\/div><\/section>\n\n\n\n
                    <\/div>
                    \n
                    \n

                    Meet Our Board of Directors<\/strong><\/h1>\n<\/div>\n<\/div><\/section>\n\n\n\n
                    <\/div>
                    \n
                    \n

                    Michael Shleifer and Albert Hummel biographies are above<\/em><\/p>\n<\/div>\n<\/div><\/section>\n\n\n\n

                    <\/div>
                    \n
                    \n
                    \"\"<\/figure>\n<\/div>\n\n\n\n
                    \n
                    Director<\/strong><\/div>\n\n\n\n

                    Bruno Montanari<\/h2>\n\n\n\n
                    • Partner of Seroba Life Sciences, a leading European venture capital fund based in Dublin<\/li>
                    • Board member of Storm Therapeutics, an RNA epigenetics-focused company in Cambridge, England and of Coave Therapeutics, a gene therapy company in Paris, France<\/li>
                    • With a background in venture capital and investment banking focused in the pharmaceutical, biotechnology and medical device industries, Bruno brings a wealth of international experience and network in emerging life sciences to Biotech Acquisition Company<\/li>
                    • We believe he is well qualified to serve as a Member of our Board due to his extensive industry, investment research, financial market and related experience<\/li>
                    • Prior positions: 
                      • Partner of Omnes Capital (Paris), where he led the life sciences investments for the venture capital team and held board positions in companies such as: 
                        • Argenx (NASDAQ: ARGX),<\/li>
                        • Poxel (EURONEXT: POXEL)<\/li>
                        • Themis (acquired by Merck & Co.)<\/li><\/ul><\/li>
                        • Principal of Atlas Venture (Paris\/London), where he sat on the boards of companies such as: 
                          • Cellzome (acquired by GlaxoSmithKline)<\/li>
                          • Newron (SWX: NWRN)<\/li>
                          • Novexel (acquired by AstraZeneca),<\/li><\/ul><\/li>
                          • Life Sciences Investment Director for Paris office of CDP Capital (Paris\/Montreal)<\/li>
                          • Board Member of iTeos (NASDAQ: ITOS)<\/li>
                          • Bruno started his career in London in the healthcare team of the investment banking divisions of Deutsche Bank and later Merrill Lynch<\/li><\/ul><\/li>
                          • Education: 
                            • MSc, Strategic Management, HEC Paris<\/li>
                            • PharmD, Universit\u00e9 Ren\u00e9 Descartes Paris V<\/li><\/ul><\/li><\/ul>\n<\/div>\n<\/div><\/section>\n\n\n\n
                              <\/div>
                              \n
                              \n
                              \"\"<\/figure>\n<\/div>\n\n\n\n
                              \n
                              Director<\/strong><\/div>\n\n\n\n

                              Paul Bernard<\/h2>\n\n\n\n
                              • Non-executive Director of Conrad Petroleum, Castle European, Sandbox Entertainment Holdings<\/li>
                              • Paul has lived and worked in Asia for 26 years<\/li>
                              • He is a CFA charterholder<\/li>
                              • We believe he is well qualified to serve as a Member of our Board due to his extensive industry, investment research, financial market and related experience<\/li>
                              • Prior positions:\u00a0
                                • Partner, private investor and Non-executive\u00a0Director of Goldman Sachs<\/li>
                                • During Paul’s 19-year career at Goldman Sachs, he built its market-leading Asia energy and chemicals research franchise and then as Co-Director of Investment Research, he built one of the leading investment research teams in Asia<\/li>
                                • Long-serving member of Goldman\u2019s Asia Management Committee involved in many of the firm\u2019s strategic growth efforts in Asia<\/li><\/ul><\/li>
                                • Education:\u00a0
                                  • MBA, Stanford University<\/li>
                                  • B.A., College of the Holy Cross<\/li><\/ul><\/li><\/ul>\n<\/div>\n<\/div><\/section>\n\n\n\n
                                    <\/div>
                                    \n
                                    \n
                                    \"\"<\/figure>\n<\/div>\n\n\n\n
                                    \n
                                    Director<\/strong><\/div>\n\n\n\n

                                    Aaron Kim<\/h2>\n\n\n\n
                                    • Co-founder\u00a0and Managing Partner of Valparaiso Capital Partners, an Asia-focused\u00a0private equity firm regionally based in Singapore, which invests in businesses and assets that provide institutional investors with specific participation on a direct investment and non-discretionary\u00a0basis<\/li>
                                    • Valparaiso co-invests, acts as the sponsor of and represents principal investors for each of its projects<\/li>
                                    • With Board level representation, larger investors have included sovereign wealth funds, public and private university endowments, insurance companies, private equity funds, and multi-family\u00a0offices<\/li>
                                    • Aaron has been involved in private equity principal investing since 1995 in Asia, leveraging his experience in technology, investment banking, and real estate development, including BSL-2\u00a0biology and chemistry laboratory facilities<\/li>
                                    • He has directly managed businesses, mergers and acquisitions, construction developments, information technology infrastructure developments, and exits for over $2\u00a0billion in transactions<\/li>
                                    • We believe he is well qualified to serve as a Member of our Board due to his extensive industry, investment research, financial market and related experience<\/li>
                                    • Prior positions:\u00a0
                                      • Executive Director, Head of Operations of AXA Japan, where he was responsible for IT and Operations, as well as business restructuring activites. He held this position when AXA acquired Nippon Group Life in 2000 for $2\u00a0billion<\/li>
                                      • Director of Corporate Finance of Brunei Investment & Commercial Bank, which is wholly-owned\u00a0by the Brunei Investment Agency, the nation\u2019s sovereign wealth fund<\/li>
                                      • Vice President of Citibank, in New York, Hong Kong and Singapore in corporate finance, advisory and strategic planning roles<\/li>
                                      • He has working fluency in Japanese and Korean, and he is an American national, originally from Menlo Park, California<\/li><\/ul><\/li>
                                      • Education:
                                        • Masters, Economics from Boston University<\/li>
                                        • B.S., Business Administration from Boston University<\/li><\/ul><\/li><\/ul>\n<\/div>\n<\/div><\/section>\n\n\n\n
                                          <\/div>
                                          \n
                                          \n

                                          Meet Our Advisor<\/strong><\/h1>\n<\/div>\n<\/div><\/section>\n\n\n\n
                                          <\/div>
                                          \n
                                          \n
                                          \"\"<\/figure>\n<\/div>\n\n\n\n
                                          \n
                                          Advisor<\/strong><\/div>\n\n\n\n

                                          Tanguy Serra<\/h2>\n\n\n\n
                                          • Co-Founder of GoodFinch, an environmental, social and governance-focused asset manager<\/li>
                                          • President and Chief Investment Officer of Loanpal, where he quickly helped the company establish its position as the top solar project lender in the U.S.<\/li>
                                          • Tanguy has extensive experience across capital markets, clean energy, and financial technology<\/li>
                                          • Prior positions: 
                                            • Co-Founder of Vivint Solar<\/li>
                                            • COO, President of SolarCity (now a subsidiary of Tesla), where he oversaw 10,000 employees and helped the company achieve 40% market share. He oversaw origination of approximately 17,000 solar systems per month and tracked performance of hundreds of thousands of systems across geographies<\/li>
                                            • Vice President of TPG Capital<\/li>
                                            • Analyst, Morgan Stanley Capital Partners<\/li>
                                            • Analyst, Merill Lynch<\/li><\/ul><\/li>
                                            • Education: 
                                              • Lycee Montaigne<\/li>
                                              • ESCP Business School<\/li><\/ul><\/li><\/ul>\n<\/div>\n<\/div><\/section>\n\n\n\n

                                                <\/p>\n\n\n\n

                                                \n
                                                \n
                                                \n

                                                Cautionary Note Concerning Forward-Looking Statements<\/em><\/strong><\/p>\n\n\n\n

                                                This communication contains statements that constitute \u201cforward-looking statements,\u201d including with respect to the\u00a0anticipated use of the net proceeds from the\u00a0Company\u2019s initial public\u00a0offering. No assurance can be given that the\u00a0net proceeds will be used as indicated. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company\u2019s\u00a0prospectus relating to the offering, which is\u00a0filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d). Copies are available on the SEC\u2019s\u00a0website, www.sec.gov. The Company undertakes no obligation to update\u00a0its forward-looking\u00a0statements, except as required by law.<\/em><\/em><\/p>\n\n\n\n

                                                No Offer or Solicitation<\/em><\/strong><\/p>\n\n\n\n

                                                The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act of 1933, as amended.<\/em><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-87","page","type-page","status-publish","hentry"],"featured_image_src":null,"featured_image_src_square":null,"_links":{"self":[{"href":"https:\/\/bioacq.com\/index.php?rest_route=\/wp\/v2\/pages\/87","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioacq.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bioacq.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bioacq.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bioacq.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=87"}],"version-history":[{"count":0,"href":"https:\/\/bioacq.com\/index.php?rest_route=\/wp\/v2\/pages\/87\/revisions"}],"wp:attachment":[{"href":"https:\/\/bioacq.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=87"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}